ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies

Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity

(2012) Marija Usenovic et al.   HUMAN MOLECULAR GENETICS

Deficiency of ATP13A2 Leads to Lysosomal Dysfunction,  -Synuclein Accumulation, and Neurotoxicity

(2012) M. Usenovic et al.   JOURNAL OF NEUROSCIENCE

The Role of the Parkinson's Disease Gene PARK9 in Essential Cellular Pathways and the Manganese Homeostasis Network in Yeast

(2012) Alessandra Chesi et al.   PLoS One

Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration

(2012) B. Dehay et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson’s disease

(2011) Jinxia Zhou et al.   ACTA NEUROPATHOLOGICA

PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity

(2011) David Ramonet et al.   HUMAN MOLECULAR GENETICS

Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism

(2011) Jin-Sung Park et al.   HUMAN MUTATION

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

(2009) Dennis W Dickson et al.   LANCET NEUROLOGY

α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity

(2009) Aaron D Gitler et al.   NATURE GENETICS